Fusen Pharmaceutical Stock code:1652.HK
Company News

Fusen pharmaceutical: metformin hydrochloride sustained release tablets passed the consistency evaluation

Fusen pharmaceutical metformin hydrochloride sustained-release tablets have successfully passed the evaluation of the consistency of quality and efficacy of generic drugs! Metformin Hydrochloride Sustained Release Tablets, a diabetes drug, has been approved by the State Administration for drug control. This product has successfully passed the quality and efficacy consistency evaluation of generic drugs, which is an authoritative recognition of the R & D capacity, production and quality management system and clinical efficacy of Fusen pharmaceutical, further highlights the product brand of Fusen pharmaceutical, helps to improve the market competitiveness of the drug, and accumulates valuable experience for the company's follow-up products to carry out generic drug consistency evaluation. ▲ notice of approval from the State Drug Administration Metformin Hydrochloride Tablets is the basic medicine for diabetes. It is used for diet and physical exercise to control type 2 diabetes patients with blood glucose inefficacy, especially obesity and hyperinsulinemia. As a first-line drug for the treatment of type II diabetes, metformin is often used in combination with other oral hypoglycemic agents. ▲ for medical professionals only Because of the superiority of metformin, it is listed as the first-line treatment for hypoglycemic treatment in the guidelines for prevention and treatment of type II diabetes, formulated by professional academic organizations both at home and abroad. As the holder of drug marketing license, Fusen pharmaceutical will not forget its original intention, forge ahead, strictly control the product quality, and constantly optimize the product layout, so that more drugs of Fusen pharmaceutical can benefit the majority of patients.
26 2022.04

Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station

Recently, the Department of human resources and social security of Guangdong Province issued a notice that the National Postdoctoral Management Committee approved Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Fusen pharmaceutical, to set up a postdoctoral scientific research workstation branch. ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. is a research and development subsidiary established by Fusen pharmaceutical in response to the national development strategy of traditional Chinese medicine. In order to enhance the independent research and development ability of traditional Chinese medicine, take the research and development of high-quality and effective traditional Chinese medicine as the main goal, and integrate the high-quality traditional Chinese medicine resources in the industry. ▲ Guangdong Macao science and Technology Industrial Park of traditional Chinese Medicine The company is located in Hengqin Guangdong Macao cooperative traditional Chinese medicine science and Technology Industrial Park. It is the first R & D platform settled in the industrial park and officially operated after the establishment of Hengqin Guangdong Macao deep cooperation zone. It is the supporting unit of the large variety cultivation sub center of traditional Chinese medicine of the national traditional Chinese medicine modernization engineering technology center. Its main business is the R & D of innovative traditional Chinese medicine and secondary development of traditional Chinese medicine, chemical medicine raw materials and preparations, light medicine and beauty products and great health products. This time, Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station, which is an affirmation of Jiaheng pharmaceutical's technological innovation ability and R & D ability, creates conditions for the company's talent training and the improvement of technological innovation ability, is conducive to further promoting the company's cooperation with universities and scientific research institutes, is conducive to the introduction of high-end R & D talents, is conducive to further improving the company's independent R & D ability and realizing the landing and transformation of scientific research achievements, Promote the sustainable innovation and development of the company and continuously improve the core competitiveness of the company.
19 2022.04

Fusen is "affectionate" and keeps "Shanghai" together | Fusen pharmaceutical donated more than 1.3 million yuan of Shuanghuanglian oral liquid and Qingre Jiedu oral liquid to support the front line of anti epidemic in Shanghai

Recently, the situation of COVID-19's prevention and control in Shanghai is grim, and the city's war epidemic is facing a tough test. In order to support Shanghai in overcoming the epidemic, giving love and giving back to the society, Fusen pharmaceutical, together with the Hong Kong young student power foundation, contacted the Shanghai Red Cross disaster preparedness and relief center, urgently allocated resources and donated drugs to the shelter of Shanghai Urban Footprint Museum and the shelter of Shanghai New International Expo Center. At present, all these equipment and materials have been sent out and are expected to arrive in Shanghai in the near future. Fusen pharmaceutical donation preparation (▲ Fusen pharmaceutical staff prepare anti epidemic materials) Shanghai aid materials ▲ materials from Fusen pharmaceutical to Shanghai Shuanghuanglian oral liquid ▲ materials from Fusen pharmaceutical to Shanghai Qingre Jiedu oral liquid Fusen Shuanghuanglian oral liquid is the first choice for the treatment of colds. At the same time, it has antibacterial and antiviral effects. It is also a family standing drug. It has been listed in the national catalogue of essential drugs and the national catalogue of medical insurance for many times. Over the past two years, Shuanghuanglian oral liquid has been listed as the recommended drug for prevention and treatment of pneumonia in New Coronavirus, Henan, Guangdong, Heilongjiang, Shaanxi and Beijing provinces. It has been widely used in epidemic prevention and control, and has made important contributions to fight against the epidemic situation. In April 2, 2022, covid-19, sponsored by the Chinese Academy of Chinese medicine, the Chinese Academy of Chinese medicine emergency branch, the Chinese Lung Association Branch of the Chinese Medicine Association and the Chinese Academy of Chinese medicine paediatric branch held the "new crown pneumonia epidemic prevention and control expert forum". Professor Wang Daowen of Tongji Medical College Affiliated to Huazhong University of Science and Technology pointed out that Shuanghuanglian oral liquid can improve the negative conversion efficiency of SARS-CoV-2 nucleic acid detection, and obviously promote mild. The absorption of inflammatory foci of pneumonia in patients with moderate and severe cov-19, combined with the standard treatment of covid-19, can enhance the antiviral effect, providing direct evidence-based medical evidence for the effectiveness and safety of covid-19 treatment. Fusen Qingre Jiedu oral liquid has the functions of antipyretic, bacteriostatic, anti-inflammatory, anti-virus and improving immunity. It is clinically used for fever, red face, irritability and thirst, sore throat caused by excessive heat toxin; Influenza and upper respiratory tract infection with the above symptoms. Shanghai aid team, let's go ▲ all donated materials of Fusen pharmaceutical have been fully packed. Go to Shanghai for support Share the robe with your son and keep "Shanghai" safe In the next few days, Fusen pharmaceutical will also Continue to pay attention to the situation of epidemic prevention and control in Shanghai Make every effort to provide support for the front line of anti epidemic The vicissitudes of the sea show their true colors, and see their original heart in times of crisis. Over the years, Fusen group has been keen on social public welfare undertakings, actively practicing social responsibility and returning the society with true feelings. It has successively donated more than 90 million yuan to the society, demonstrating the responsibility of the enterprise and the feelings of home and country with practical actions.
19 2022.04
Previous page



Copyright © 2021 Fusen Pharmaceutical Company Limited

豫ICP备2021028871号  Powered by

Copyright © 2021 Fusen Pharmaceutical  All Rights Reserved.      豫ICP备2021028871号        Powered by